Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Related Keywords

New Zealand ,Australia ,Edna Kaplan ,Paula Schwartz ,Jessica Breu ,Daiichi Sankyo ,Andreas Muehler ,Daniel Vitt ,Exchange Commission ,Daiichi Sankyo Co Ltd ,Rx Communications Group ,Prnewswire Immunic Inc ,Nasdaq ,Immunic Inc ,First Time Patients Will ,Intestinal Barrier Function ,Bowel Epithelium ,Chief Executive Officer ,Chief Medical Officer ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Immunic ,Nc ,